PF-Atlas › Clinical Trials › NCT03069248

Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon

Rituximab · Phase 2

Registry ID
NCT03069248
Phase
Phase 2
Status
Completed
Drug / intervention
Rituximab
Sponsor
Sunnybrook Health Sciences Centre
Start
2000-06-01
Enrollment
36
Locations
1

About this trial

This is a non-comparative, prospective, non-randomized single centre phase II clinical trial of Rituximab and alpha interferon immunotherapy following autologous stem cell transplant in patients with relapsed follicular lymphoma conducted at Toronto Sunnybrook Regional Cancer Centre/Sunnybrook and Women's Health Sciences Centre.

View NCT03069248 on ClinicalTrials.gov →

Explore related

All Rituximab trialsAll IPF trials

Related trials

Rituximab — NCT01086540Rituximab — NCT01862926Rituximab — NCT02990286Rituximab — NCT05596786Rituximab — NCT01969409Rituximab — NCT01748084
Medical disclaimer. This page summarizes public trial data for NCT03069248 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.